This is a vital step in preparation to initiate FDA Phase I human clinical trials.
We have significantly de-risked the development of our lead drug candidate MB-204 and have a strong understanding of its safety and risk profile, as we have redeveloped this candidate from an existing FDA-approved drug Istradefylline,' said
After completing the maximum tolerated single dose studies, the FDA requires another short study before entering the industry standard Good Lab Practice (GLP) toxicology studies. This study requires toxicology studies in two species, typically rats and dogs, to test the safety of new drugs before being able to run trials on humans.
This is the final milestone experiment we need to execute in order to identify the optimal doses for our upcoming 4-week GLP rat study, which in combination with our dog studies, will allow us to start human clinical testing of MB-204,' said Dr.
MB-204 is a fluorinated derivative of the
About
Contact:
Tel: 416-644-5081
Email: info@virtusadvisory.com
All information contained in this news release with respect to the Company and its subsidiary, (collectively, the 'Parties') were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
(C) 2022 Electronic News Publishing, source